AC Immune SA (ACIU)

2.45 +0.05 (+2.08%) USD  |  NASDAQ  |  Oct 15, 16:00
2.45 0.00 (0.00%) After-Hours: 20:00
More

AC Immune Research and Development Expense (Quarterly) : 13.25M for June 30, 2026

Research and Development Expense (Quarterly) Chart

Historical Research and Development Expense (Quarterly) Data

View and export this data back to 2015. Start Trial.
Date Value
June 30, 2026 13.25M
March 31, 2026 14.99M
December 31, 2025 13.29M
September 30, 2025 16.33M
June 30, 2025 20.35M
March 31, 2025 17.70M
December 31, 2024 17.99M
September 30, 2024 16.71M
June 30, 2024 18.95M
March 31, 2024 17.34M
December 31, 2023 16.51M
September 30, 2023 14.04M
June 30, 2023 15.22M
March 31, 2023 14.99M
December 31, 2022 15.70M
September 30, 2022 14.88M
June 30, 2022 16.26M
March 31, 2022 16.37M
December 31, 2021 21.83M
September 30, 2021 16.46M
June 30, 2021 15.06M
March 31, 2021 14.71M
Date Value
December 31, 2020 17.65M
September 30, 2020 16.87M
June 30, 2020 13.29M
March 31, 2020 15.71M
December 31, 2019 14.81M
September 30, 2019 11.64M
June 30, 2019 12.67M
March 31, 2019 11.63M
December 31, 2018 12.18M
September 30, 2018 11.48M
June 30, 2018 10.44M
March 31, 2018 10.41M
December 31, 2017 10.11M
September 30, 2017 8.346M
June 30, 2017 6.804M
March 31, 2017 7.330M
December 31, 2016 6.969M
September 30, 2016 7.828M
June 30, 2016 5.740M
March 31, 2016 5.342M
December 31, 2015 5.682M
September 30, 2015 4.232M

R&D Expense Definition

R&D expense is a line item from many companies' income statements.

Read full definition.

Research and Development Expense (Quarterly) Range, Past 5 Years

View Research and Development Expense (Quarterly) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Research and Development Expense (Quarterly) Benchmarks

View Research and Development Expense (Quarterly) Benchmarks
Start Trial
Precigen, Inc. 6.963M
Basilea Pharmaceutica AG --
Santhera Pharmaceuticals Holding AG --
Aldeyra Therapeutics, Inc. 3.484M
BeOne Medicines Ltd. 593.46M